每年研究成果
每年研究成果
- 8結果
搜尋結果
-
2024
Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)
Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., 7月 2024, 於: Cell Death and Disease. 15, 7, 490.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
2023
Erratum: N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling (J. Med. Chem. (2015) 58:16 (6549−6558) DOI: 10.1021/acs.jmedchem.5b00659)
Lai, M. J., Lee, H. Y., Chuang, H. Y., Chang, L. H., Tsai, A. C., Chen, M. C., Huang, H. L., Wu, Y. W., Teng, C. M., Pan, S. L., Liu, Y. M., Mehndiratta, S. & Liou, J. P., 5月 11 2023, 於: Journal of Medicinal Chemistry. 66, 9, p. 6436 1 p.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
2020
Corrigendum to “1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma” [Eur. J. Med. Chem. 140 (2017) 84–91](S0223523417306931)(10.1016/j.ejmech.2017.09.011)
Liu, Y. M., HuangFu, W. C., Huang, H. L., Wu, W. C., Chen, Y. L., Yen, Y., Huang, H. L., Nien, C. Y., Lai, M. J., Pan, S. L. & Liou, J. P., 9月 15 2020, 於: European Journal of Medicinal Chemistry. 202, 112633.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取2 引文 斯高帕斯（Scopus） -
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., 6月 15 2020, 於: European Journal of Medicinal Chemistry. 196, 112329.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., 9月 1 2020, 於: European Journal of Medicinal Chemistry. 201, 112404.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
1 引文 斯高帕斯（Scopus） -
Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))
Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., 8月 1 2020, 於: European Journal of Medicinal Chemistry. 199, 112406.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
2013
Erratum: MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mrna through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR (Molecular Cancer Therapeutics (2013) 12 (1202-12))
Cheng, Y. C., Liou, J. P., Kuo, C. C., Lai, W. Y., Shih, K. H., Chang, C. Y., Pan, W. Y., Tseng, J. T. & Chang, J. Y., 9月 2013, 於: Molecular Cancer Therapeutics. 12, 9, p. 1919 1 p.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
-
2003
Erratum: Structure-activity and crystallographic analysis of benzophenone derivatives - The potential anticancer agents (Bioorganic and Medicinal Chemistry Letters (2003) 13 (101) PII S0960894X02008508)
Hsieh, H. P., Liou, J. P., Lin, Y. T., Mahindroo, N., Chang, J. Y., Yang, Y. N., Chern, S. S., Tan, U. K., Chang, C. W., Chen, T. W., Lin, C. H., Chang, Y. Y. & Wang, C. C., 3月 10 2003, 於: Bioorganic and Medicinal Chemistry Letters. 13, 5, p. 977 1 p.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審